Catalysis deactivated angiotensin-converting enzyme 2 (ACE2) variants and their uses
AssigneeAvirmax, Inc.
InventorShengjiang Liu
Life of this patent
Estimating the term…
Abstract
Angiotensin-converting enzyme 2 (ACE2) has been confirmed as a specific receptor for several (3 group coronaviruses include severe respiratory syndrome (SARS) coronavirus (SARS-CoV-1) and recently the causative agent for the World pandemic CoVID-19, SARS-CoV-2, and low pathogenic coronavirus of HCoV-NL63, a member in α-coronavirus group. Viral spike protein (S) of viral envelope is confirmed to bind to ACE2 as viral receptor to start a virus replication cycle. The present invention provides ACE2 and its mutants or variants, the viral or non-viral vectors thereof. Methods of treatment of viral infection of a human subject by using such mutants or variants are also provided.
Claims5
An isolated angiotensin converting enzyme 2 (ACE2) polypeptide with one or more mutations relative to the wild-type ACE2 that cause the loss of ACE2 enzymatic activity comparing to the wild-type ACE2, the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs 3, 4, 10, 17, and 18.
Dependencies are inferred from the claim text.